These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38558141)

  • 21. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study.
    Gordon E; Rohrer JD; Kim LG; Omar R; Rossor MN; Fox NC; Warren JD
    Neurology; 2010 Feb; 74(8):666-73. PubMed ID: 20177120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.
    Staffaroni AM; Bajorek L; Casaletto KB; Cobigo Y; Goh SM; Wolf A; Heuer HW; Elahi FM; Ljubenkov PA; Dever R; Kornak J; Appleby B; Bove J; Bordelon Y; Brannelly P; Brushaber D; Caso C; Coppola G; Dheel C; Dickerson BC; Dickinson S; Dominguez S; Domoto-Reilly K; Faber K; Ferrall J; Fields JA; Fishman A; Fong J; Foroud T; Forsberg LK; Gavrilova R; Gearhart D; Ghazanfari B; Ghoshal N; Goldman J; Graff-Radford J; Graff-Radford N; Grant I; Grossman M; Haley D; Hsiung GY; Huey ED; Irwin DJ; Jones DT; Jones L; Kantarci K; Karydas A; Kaufer DI; Kerwin DR; Knopman DS; Kraft R; Kremers WK; Kukull WA; Litvan I; Lucente D; Lungu C; Mackenzie IR; Maldonado M; Manoochehri M; McGinnis SM; McKinley E; Mendez MF; Miller BL; Multani N; Onyike C; Padmanabhan J; Pantelyat A; Pearlman R; Petrucelli L; Potter M; Rademakers R; Ramos EM; Rankin KP; Rascovsky K; Roberson ED; Rogalski E; Sengdy P; Shaw LM; Syrjanen J; Tartaglia MC; Tatton N; Taylor J; Toga A; Trojanowski JQ; Weintraub S; Wang P; Wong B; Wszolek Z; Boxer AL; Boeve BF; Kramer JH; Rosen HJ;
    Alzheimers Dement; 2020 Jan; 16(1):11-21. PubMed ID: 31914230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remote Self-Administration of Cognitive Screeners for Older Adults Prior to a Primary Care Visit: Pilot Cross-Sectional Study of the Reliability and Usability of the MyCog Mobile Screening App.
    Young SR; Dworak EM; Byrne GJ; Jones CM; Yao L; Yoshino Benavente JN; Diaz MV; Curtis L; Gershon R; Wolf M; Nowinski CJ
    JMIR Form Res; 2024 Feb; 8():e54299. PubMed ID: 38324368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
    Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
    Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort.
    Balasa M; Gelpi E; Martín I; Antonell A; Rey MJ; Grau-Rivera O; Molinuevo JL; Sánchez-Valle R; Lladó A;
    Neuropathol Appl Neurobiol; 2015 Dec; 41(7):882-92. PubMed ID: 25381753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration.
    Knopman DS; Kramer JH; Boeve BF; Caselli RJ; Graff-Radford NR; Mendez MF; Miller BL; Mercaldo N
    Brain; 2008 Nov; 131(Pt 11):2957-68. PubMed ID: 18829698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presymptomatic and early pathological features of MAPT-associated frontotemporal lobar degeneration.
    Giannini LA; Mol MO; Rajicic A; van Buuren R; Sarkar L; Arezoumandan S; Ohm DT; Irwin DJ; Rozemuller AJ; ; van Swieten JC; Seelaar H
    Acta Neuropathol Commun; 2023 Aug; 11(1):126. PubMed ID: 37533060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presenting neuropsychological testing profile of autopsy-confirmed frontotemporal lobar degeneration.
    Yoshizawa H; Vonsattel JP; Honig LS
    Dement Geriatr Cogn Disord; 2013; 36(5-6):279-89. PubMed ID: 23949428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study.
    Pratap A; Grant D; Vegesna A; Tummalacherla M; Cohan S; Deshpande C; Mangravite L; Omberg L
    JMIR Mhealth Uhealth; 2020 Oct; 8(10):e22108. PubMed ID: 33107827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurocognitive speed associates with frontotemporal lobar degeneration TDP-43 subtypes.
    Dean PM; Smith GE; Parisi JE; Dickson DW; Petersen RC; Josephs KA
    J Clin Neurosci; 2013 Dec; 20(12):1737-41. PubMed ID: 24012243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.
    Cervantes González A; Irwin DJ; Alcolea D; McMillan CT; Chen-Plotkin A; Wolk D; Sirisi S; Dols-Icardo O; Querol-Vilaseca M; Illán-Gala I; Santos-Santos MA; Fortea J; Lee EB; Trojanowski JQ; Grossman M; Lleó A; Belbin O
    Mol Neurodegener; 2022 Apr; 17(1):29. PubMed ID: 35395770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration.
    McMillan CT; Irwin DJ; Avants BB; Powers J; Cook PA; Toledo JB; McCarty Wood E; Van Deerlin VM; Lee VM; Trojanowski JQ; Grossman M
    J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):949-55. PubMed ID: 23475817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological correlates in the frontotemporal lobar degeneration-motor neuron disease spectrum.
    Carbayo Á; Borrego-Écija S; Turon-Sans J; Cortés-Vicente E; Molina-Porcel L; Gascón-Bayarri J; Rubio MÁ; Povedano M; Gámez J; Sotoca J; Juntas-Morales R; Almendrote M; Marquié M; Sánchez-Valle R; Illán-Gala I; Dols-Icardo O; Rubio-Guerra S; Bernal S; Caballero-Ávila M; Vesperinas A; Gelpi E; Rojas-García R
    Brain; 2024 Jul; 147(7):2357-2367. PubMed ID: 38227807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease.
    Das S; van Engelen ME; Goossens J; Jacobs D; Bongers B; Fieldhouse JLP; Pijnenburg YAL; Teunissen CE; Vanmechelen E; Verberk IMW
    Alzheimers Res Ther; 2024 Feb; 16(1):34. PubMed ID: 38355535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Looking for Measures of Disease Severity in the Frontotemporal Dementia Continuum.
    Premi E; Gualeni V; Costa P; Cosseddu M; Gasparotti R; Padovani A; Borroni B
    J Alzheimers Dis; 2016 Apr; 52(4):1227-35. PubMed ID: 27104906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort.
    Peakman G; Russell LL; Convery RS; Nicholas JM; Van Swieten JC; Jiskoot LC; Moreno F; Sanchez-Valle R; Laforce R; Graff C; Masellis M; Tartaglia MC; Rowe JB; Borroni B; Finger E; Synofzik M; Galimberti D; Vandenberghe R; de Mendonça A; Butler CR; Gerhard A; Ducharme S; Le Ber I; Tagliavini F; Santana I; Pasquier F; Levin J; Danek A; Otto M; Sorbi S; Rohrer JD;
    J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):158-168. PubMed ID: 34353857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive composites for genetic frontotemporal dementia: GENFI-Cog.
    Poos JM; Moore KM; Nicholas J; Russell LL; Peakman G; Convery RS; Jiskoot LC; van der Ende E; van den Berg E; Papma JM; Seelaar H; Pijnenburg YAL; Moreno F; Sanchez-Valle R; Borroni B; Laforce R; Masellis M; Tartaglia C; Graff C; Galimberti D; Rowe JB; Finger E; Synofzik M; Vandenberghe R; de Mendonça A; Tiraboschi P; Santana I; Ducharme S; Butler C; Gerhard A; Levin J; Danek A; Otto M; Le Ber I; Pasquier F; van Swieten JC; Rohrer JD;
    Alzheimers Res Ther; 2022 Jan; 14(1):10. PubMed ID: 35045872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Choroid Plexus Volume With Serum Biomarkers, Clinical Features, and Disease Severity in Patients With Frontotemporal Lobar Degeneration Spectrum.
    Assogna M; Premi E; Gazzina S; Benussi A; Ashton NJ; Zetterberg H; Blennow K; Gasparotti R; Padovani A; Tadayon E; Romanella S; Sprugnoli G; Pascual-Leone A; Di Lorenzo F; Koch G; Borroni B; Santarnecchi E
    Neurology; 2023 Sep; 101(12):e1218-e1230. PubMed ID: 37500561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility and initial validation of 'HD-Mobile', a smartphone application for remote self-administration of performance-based cognitive measures in Huntington's disease.
    McLaren B; Andrews SC; Glikmann-Johnston Y; Mercieca EC; Murray NWG; Loy C; Bellgrove MA; Stout JC
    J Neurol; 2021 Feb; 268(2):590-601. PubMed ID: 32880724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.